We all rely on medicines. But they don’t always work as intended. Too often, they’re held back by fundamental limitations such as side effects or no targeting. We are here to change this. ProSilic® is our bio-courier engineered to maximise the therapeutic benefits of drug molecules and active ingredients.
We are a commercial-stage drug development company. Our pharmaceutical pipeline is focussed on reformulating existing medicines to make them more effective. We also develop formulations for clients, our own subsidiaries and grant-funded R&D projects.
Led by entrepreneur, inventor, and scientist, Dr Suzanne Saffie-Siebert, our management team has a wealth of executive experience in pharmaceutics, skincare and animal health.
ProSilic® is our patented bio-courier technology. It’s a hybrid of porous silicon and liposomes and can be engineered to take even the most challenging molecules to their target, optimising efficacy and safety.
New drug discovery is expensive, time consuming and risky.
We’re focussed on a faster, lower risk approach to drug development.
Croda Invests in SiSaf’s Novel Bio-Courier TechnologyMore
UK based biopharmaceutical company SiSaf closes $4.3 million interim funding roundMore
SiSaf’s Chairwoman and Chief Executive Officer, Suzanne Saffie-Siebert featured on BBC Radio 4’s ‘In Business’More
Next-gen silicon nanotechnology drug delivery company SiSaf raises $3.5 million in Series A FundingMore
Silicon Valley Investors Lead Funding Round in SiSafMore
SiSaf Releases latest Clinical Data Showing a 95% Reduction in AcneMore